Preparations have begun for the prescription of Lorviqua, a third-generation ALK that seeks to register insurance benefits. According to related industries, Lorviqua of Pfizer Korea passed DC of medical institutions such as Gangnam Severance Hospital, National Cancer Center, Chung-Ang University Hospital, and Hanyang University Hospital, as well as Samsung Medical Center and Seoul National University Hospital. It is aiming to settle down in the market quickly in case it succeeds in registering salaries.

Lorviqua, which first passed the HIRA's cancer disease review committee in January 2022, is currently waiting for the introduction of the Drug Reimbursement Evaluation Committee. Since Lorviqua is a drug